Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Inclusion Criteria:

1. 18 years of age or older

2. Ability to understand and the willingness to provide written informed consent

3. Having or suspected of having cardiac disease

4. Undergone a transthoracic echo within 30 days prior to NH002 dose administration,resulting in suboptimal LVEBD, as defined by 2 or more segments of 6 segments of theventricular border that cannot be visualized reliably in any of the standard apical 4-, 2-, and 3-chamber views during the resting non-contrast ultrasound examination

Exclusion Criteria:

Subjects will be excluded from the study if one or more of the following exclusion criteria are applicable:

1. Any evidence of other severe or unstable cardiopulmonary and/or systemic hemodynamicconditions deemed unsuitable for the study by the investigator(s) prior to NH002dose administration, including, but not limited to:

2. ongoing or recent acute coronary syndrome within 6 months.

3. uncontrolled serious ventricular arrhythmias.

4. decompensated or inadequately controlled congestive heart failure (New YorkHeart Association Class IV).

5. atrial fibrillation or current uncontrolled cardiac arrhythmias causingsymptoms or hemodynamic compromise.

6. uncontrolled hypertension (i.e., resting systolic blood pressure >200 mmHg ordiastolic blood pressure >110 mmHg or arterial hypotension [defined as systolicblood pressure ≤ 90 mmHg]).

7. acute aortic dissection.

8. Known or suspected hypersensitivity to one or more of the ingredients of NH002,perflutren, Definity®, or other echocardiographic contrast agents

9. Known or suspected hypersensitivity to polyethylene glycol, prior reactions tocommon polyethylene glycol-containing products such as colonoscopy bowelpreparations, and certain laxatives (e.g., Miralax)

10. Received an investigational compound within 30 days before enrolling in the study

11. Received any contrast agent either intravascularly or orally within 48 hours priorto NH002 dose administration

12. Pregnant or lactating female. Exclude the possibility of pregnancy:

13. testing on-site at the institution (serum or urine β-human chorionicgonadotropin) within 24 hours prior to the start of NH002 dose administration,and

14. history of using an adequate and medically approved method of contraception toavoid pregnancy for at least 1 month prior to NH002 dose administration andwilling to continue using the same method for the duration of the study, or

15. surgical history (e.g., tubal ligation or hysterectomy), or

16. postmenopausal with a minimum of 1 year without menses.

17. Serious medical or psychiatric illness/condition likely, in the judgment of theinvestigator, to interfere with compliance to protocol treatment/research